^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BB-1701

    i
    Company:
    BlissBio
    Drug class:
    Microtubule inhibitor, HER2-targeted antibody-drug conjugate
    Related drugs:
    Apply
    A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors (NCT04257110)
    Phase 1
    Bliss Biopharmaceutical (Hangzhou) Co., Ltd
    Active, not recruiting
    Last update posted :
    12/15/2023
    Initiation :
    07/28/2020
    Primary completion :
    08/01/2024
    Completion :
    12/01/2024
    HER-2 • ER • PGR
    |
    HER-2 expression
    |
    BB-1701